RCUS
Arcus Biosciences, Inc.
NYSE · Healthcare · Biotechnology · US
$29.66
−1.56%Margins
Gross margin
94.0%
EBITDA margin
-358.1%
EBIT margin
-415.4%
Net margin
-386.3%
FCF margin
-406.0%
-97.4%
Return on equity
-48.9%
Return on assets
-84.1%
Return on invested capital
0.12x
Asset turnover
-$474.0M
Cash from operations
$5.51
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026